• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

肾癌：下一个十年。

Kidney cancer: The next decade.

机构信息

Francis Crick Institute, London, UK.

The Royal Marsden Hospital, London, UK.

出版信息

J Exp Med. 2018 Oct 1;215(10):2477-2479. doi: 10.1084/jem.20181617. Epub 2018 Sep 14.

DOI:10.1084/jem.20181617
PMID:30217855
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6170181/
Abstract

Chris Boshoff, Senior Vice President of Immuno-Oncology, Translational and Early Development at Pfizer, and colleagues Samra Turajlic and Charles Swanton from the Francis Crick Institute and University College London give us their personal point of view on new insights and future therapeutic approaches for renal cancer.

摘要

辉瑞公司免疫肿瘤学、转化和早期研发高级副总裁克里斯·博肖夫（Chris Boshoff）和弗朗西斯·克里克研究所（Francis Crick Institute）及伦敦大学学院的同事萨默拉·图拉利奇（Samra Turajlic）和查尔斯·斯旺顿（Charles Swanton）从个人角度探讨了肾癌的新见解和未来治疗方法。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4305/6170181/4b629fa14687/JEM_20181617_Fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4305/6170181/4b629fa14687/JEM_20181617_Fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4305/6170181/4b629fa14687/JEM_20181617_Fig1.jpg

相似文献

1
Kidney cancer: The next decade.肾癌：下一个十年。
J Exp Med. 2018 Oct 1;215(10):2477-2479. doi: 10.1084/jem.20181617. Epub 2018 Sep 14.
2
Editorial comment.编辑评论。
J Urol. 2010 Apr;183(4):1315-6; discussion 1316. doi: 10.1016/j.juro.2009.12.125. Epub 2010 Feb 19.
3
Impact of histologic subtyping of renal epithelial neoplasms.肾上皮性肿瘤组织学亚型的影响
Am J Surg Pathol. 2003 Jul;27(7):1021-2; author reply 1022-4. doi: 10.1097/00000478-200307000-00022.
4
Prognostic factors in renal cell carcinoma.肾细胞癌的预后因素。
Scand J Surg. 2004;93(2):118-25. doi: 10.1177/145749690409300206.
5
Update on pathologic staging of renal cell carcinoma.肾细胞癌病理分期的最新进展。
Urology. 2002 Aug;60(2):209-17. doi: 10.1016/s0090-4295(02)01675-8.
6
Sarcomatoid renal cell carcinoma: an examination of underlying histologic subtype and an analysis of associations with patient outcome.肉瘤样肾细胞癌：潜在组织学亚型的检查及与患者预后相关性的分析
Int Braz J Urol. 2004 Jul-Aug;30(4):347-8.
7
Diagnosis and classification of renal cell carcinoma.肾细胞癌的诊断与分类
Urol Clin North Am. 1999 Aug;26(3):627-35. doi: 10.1016/s0094-0143(05)70203-2.
8
Staging and survival of patients with renal cell carcinoma.肾细胞癌患者的分期与生存情况。
Semin Surg Oncol. 1994 Jan-Feb;10(1):47-50. doi: 10.1002/ssu.2980100108.
9
Nuclear grooves in papillary (chromophil) renal cell carcinoma.乳头状（嗜色性）肾细胞癌中的核沟。
Am J Surg Pathol. 1998 Oct;22(10):1298-300. doi: 10.1097/00000478-199810000-00019.
10
Is there a need to further subclassify pT2 renal cell cancers as implemented by the revised 7th TNM version?是否需要按照修订后的第 7 版 TNM 分期进一步对 pT2 肾细胞癌进行亚分类？
Eur Urol. 2011 Feb;59(2):258-63. doi: 10.1016/j.eururo.2010.10.005. Epub 2010 Oct 15.

引用本文的文献

1
GFOD1 expression in clear cell renal cell carcinoma and its role in cancer cell proliferation, migration, and invasion.GFOD1在透明细胞肾细胞癌中的表达及其在癌细胞增殖、迁移和侵袭中的作用。
Discov Oncol. 2025 Jul 1;16(1):1212. doi: 10.1007/s12672-025-03049-2.
2
Rising incidence and clinical impact of kidney cancer in China and worldwide: a call for targeted prevention, early diagnosis, and equitable treatment.中国及全球肾癌发病率上升及其临床影响：呼吁进行针对性预防、早期诊断和公平治疗。
Transl Androl Urol. 2025 May 30;14(5):1391-1407. doi: 10.21037/tau-2024-750. Epub 2025 May 27.
3
Clinicopathological-based nomogram prediction and molecular characterization of postoperative recurrence in clinical T1 clear cell renal cell carcinoma.

本文引用的文献

1
Tumor innate immunity primed by specific interferon-stimulated endogenous retroviruses.特定干扰素刺激的内源性逆转录病毒预先激活的肿瘤固有免疫。
Nat Med. 2018 Aug;24(8):1143-1150. doi: 10.1038/s41591-018-0116-5. Epub 2018 Jul 23.
2
Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma.阿替利珠单抗单药或联合贝伐珠单抗与舒尼替尼治疗肾细胞癌的临床活性和分子相关性。
Nat Med. 2018 Jun;24(6):749-757. doi: 10.1038/s41591-018-0053-3. Epub 2018 Jun 4.
3
Tracking Cancer Evolution Reveals Constrained Routes to Metastases: TRACERx Renal.
基于临床病理的列线图预测及临床T1期透明细胞肾细胞癌术后复发的分子特征分析
BMC Surg. 2025 Jun 5;25(1):247. doi: 10.1186/s12893-025-02991-w.
4
Disclosing the development and focus of sequencing and omics studies in kidney neoplasm research.揭示肾脏肿瘤研究中测序和组学研究的发展与重点。
Discov Oncol. 2025 May 26;16(1):928. doi: 10.1007/s12672-025-02750-6.
5
Global Burden of Kidney Cancer Attributable to High Body Mass Index in Adults Aged 60 and Older from 1990 to 2021 and Projections to 2040: A Systematic Analysis for the Global Burden of Disease Study.1990年至2021年60岁及以上成年人中归因于高体重指数的肾癌全球负担及到2040年的预测：全球疾病负担研究的系统分析
Clin Epidemiol. 2025 May 21;17:453-479. doi: 10.2147/CLEP.S521272. eCollection 2025.
6
Metabolic reprogramming and immune microenvironment profiling in clear cell renal cell carcinoma: implications for prognosis, targeted therapy, and drug resistance.透明细胞肾细胞癌中的代谢重编程与免疫微环境分析：对预后、靶向治疗及耐药性的意义
Discov Oncol. 2025 May 21;16(1):850. doi: 10.1007/s12672-025-02401-w.
7
Construction and validation of renal cell carcinoma tumor cell differentiation-related prognostic classification (RCC-TCDC): an integrated bioinformatic analysis and clinical study.肾细胞癌肿瘤细胞分化相关预后分类（RCC-TCDC）的构建与验证：一项综合生物信息学分析和临床研究
Ann Med. 2025 Dec;57(1):2490830. doi: 10.1080/07853890.2025.2490830. Epub 2025 Apr 18.
8
Identification and validation of prognostic biomarkers in ccRCC: immune-stromal score and survival prediction.肾透明细胞癌中预后生物标志物的鉴定与验证：免疫-基质评分与生存预测
BMC Cancer. 2025 Jan 27;25(1):148. doi: 10.1186/s12885-025-13534-0.
9
High-throughput methylation sequencing reveals novel biomarkers for the early detection of renal cell carcinoma.高通量甲基化测序揭示了用于早期检测肾细胞癌的新型生物标志物。
BMC Cancer. 2025 Jan 16;25(1):96. doi: 10.1186/s12885-024-13380-6.
10
CLIP170 enhancing FOSL1 expression via attenuating ubiquitin-mediated degradation of β-catenin drives renal cell carcinoma progression.CLIP170 通过减弱 β-连环蛋白的泛素介导降解来增强 FOSL1 的表达，从而驱动肾细胞癌的进展。
Cell Mol Life Sci. 2024 Nov 28;81(1):467. doi: 10.1007/s00018-024-05504-9.
追踪癌症演进揭示转移受限途径：TRACERx 肾脏。
Cell. 2018 Apr 19;173(3):581-594.e12. doi: 10.1016/j.cell.2018.03.057. Epub 2018 Apr 12.
4
Deterministic Evolutionary Trajectories Influence Primary Tumor Growth: TRACERx Renal.确定性进化轨迹影响原发性肿瘤生长：TRACERx 肾脏。
Cell. 2018 Apr 19;173(3):595-610.e11. doi: 10.1016/j.cell.2018.03.043. Epub 2018 Apr 12.
5
Timing the Landmark Events in the Evolution of Clear Cell Renal Cell Cancer: TRACERx Renal.追踪肾脏研究：明确肾细胞癌演进过程中的里程碑事件。
Cell. 2018 Apr 19;173(3):611-623.e17. doi: 10.1016/j.cell.2018.02.020. Epub 2018 Apr 12.
6
Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma.透明细胞肾细胞癌中免疫检查点疗法反应的基因组相关性
Science. 2018 Feb 16;359(6377):801-806. doi: 10.1126/science.aan5951. Epub 2018 Jan 4.
7
Deficiency Drives Enhancer Activation of Oncogenes in Clear Cell Renal Cell Carcinoma.抑素缺乏驱动透明细胞肾细胞癌中癌基因的增强子激活。
Cancer Discov. 2017 Nov;7(11):1284-1305. doi: 10.1158/2159-8290.CD-17-0375. Epub 2017 Sep 11.
8
Insertion-and-deletion-derived tumour-specific neoantigens and the immunogenic phenotype: a pan-cancer analysis.插入缺失衍生的肿瘤特异性新抗原和免疫表型：泛癌分析。
Lancet Oncol. 2017 Aug;18(8):1009-1021. doi: 10.1016/S1470-2045(17)30516-8. Epub 2017 Jul 7.
9
Systemic Therapy for Metastatic Renal-Cell Carcinoma.转移性肾细胞癌的全身治疗
N Engl J Med. 2017 Jan 26;376(4):354-366. doi: 10.1056/NEJMra1601333.
10
Genome-Driven Paradigm for the Development of Selective Fibroblast Growth Factor Receptor Inhibitors.用于开发选择性成纤维细胞生长因子受体抑制剂的基因组驱动范式
J Clin Oncol. 2017 Jan 10;35(2):131-134. doi: 10.1200/JCO.2016.70.5061. Epub 2016 Dec 5.